Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Group 1 - Sagimet Biosciences Inc. (NASDAQ: SGMT) has shown significant improvement and is positioned as a potential leader in innovative therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1] - The company may soon explore additional applications in dermatology and oncology [1] - A Strong Buy rating was previously issued in July, indicating positive sentiment towards the company's prospects [1]